Juvenescence

Juvenescence

Juvenescence is a venture capital and development company focused on developing therapies targeting aging, age-related disease and regeneration.

Juvenescence is a Douglas, Isle of Man based venture capital and development company. They focus their investments and development on companies developing therapeutic strategies to treat the tissue-specific signature and pathologies of aging and senescence. The strategy includes products targeted at slowing cellular aging, slowing and reversing neurodegeneration, destroying senescent cells, replacing aging organs and editing patient genes.

Investment

Juvenescence has invested in LyGenesis, Souvien Therapeutics, BYOMass, BHB Therapeutics, AgeX Therapeutics, Napa Therapeutics, FoxBio, Insilico Medicine, GenerAIt Pharmaceuticals and Netrapharma.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
LyGenesis

Organic regeneration using lymph nodes company

BioTime is an Alameda, California-based company.

2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Juvenescence funding round, August 2019
100,000,000
August 2019
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alexander Pickett

Managing Director

Benjamin Swerner

Director

Chris Shilling

Project Manager

Christine Curioso

Executive Assistant

Colin Watts

CEO of Juvenescence Life

David Ellam

Chief Financial Officer

Dr. Declan Doogan

Chief Medical Officer

Dr. Gregory Bailey

Chief Executive Officer

Dr. Jake P. Taylor-King

Director

Dr. Margaret Jackson

Head of Preclinical R&D

Dr. Martin Ducker

Director

Dr. Nafees Malik

Head of Cell and Gene Therapy

Dr. Raj S. Dattani

Director

Jim Mellon

Chairman

Yehudah Nevies

Associate Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 11, 2020
BioSpace
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team.
BioSpace
May 21, 2020
BioSpace
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human longevity, is pleased to announce the appointment of Dr. Jean-Christophe Renondin to its Main Board of Directors, and of Dr. David Roblin and Dr. Steve Felstead to its Senior Leadership Team.
By Tim Collins For Mailonline
August 19, 2019
Mail Online
The firm announced a total investment of $10 million from its founders and a further $10 million each from core investors.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.